<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="153">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2015</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01739361</url>
  </required_header>
  <id_info>
    <org_study_id>APAP-121486</org_study_id>
    <nct_id>NCT01739361</nct_id>
  </id_info>
  <brief_title>Acetaminophen for the Reduction of Oxidative Injury in Severe Sepsis</brief_title>
  <acronym>ACROSS</acronym>
  <official_title>Phase IIa Randomized Controlled Trial of Acetaminophen for the Reduction of Oxidative Stress in Severe Sepsis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vanderbilt University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Vanderbilt University</source>
  <oversight_info>
    <authority>United States: Data and Safety Monitoring Board</authority>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Cell-free hemoglobin can be measured in the plasma of patients with sickle cell anemia,
      hemodialysis, after red blood cell transfusion, and in patients with sepsis. Cell-free
      hemoglobin in these patient population has been associated with poor outcomes, including an
      association with an increased risk of death. Acetaminophen may have a protective effect in
      these patient populations by inhibiting hemoprotein-mediated lipid peroxidation. The purpose
      of the present trial is to study the effect of acetaminophen on lipid peroxidation in adults
      with severe sepsis and detectable cell-free hemoglobin.

      The primary hypothesis is that systemic markers of oxidative stress and lipid peroxidation,
      as measured by F2-isoprostanes, will be significantly lower in patients with severe sepsis
      and detectable cell-free hemoglobin who receive acetaminophen compared to placebo. The
      secondary hypothesis is that patients with severe sepsis and detectable cell-free hemoglobin
      treated with acetaminophen will have better clinical outcomes, including decreased incidence
      of acute kidney injury and lower rates of hospital mortality, compared to those who receive
      placebo.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2013</start_date>
  <completion_date type="Actual">December 2013</completion_date>
  <primary_completion_date type="Actual">December 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>F2-isoprostanes After 72 Hours of Acetaminophen or Placebo</measure>
    <time_frame>72 hours after randomization</time_frame>
    <safety_issue>No</safety_issue>
    <description>F2-isoprostanes are a marker of oxidative stress, specifically lipid peroxidation.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>In-hospital Mortality</measure>
    <time_frame>Patients will be followed through the end of their hospital stay, an average of 5 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Creatinine After 72 Hours of Treatment With Acetaminophen or Placebo, Adjusted for Baseline Creatinine</measure>
    <time_frame>72 hours</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">44</enrollment>
  <condition>Severe Sepsis</condition>
  <arm_group>
    <arm_group_label>Acetaminophen</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive acetaminophen at the dose of 1 gram by mouth or by enteral feeding tube every six hours for a total of 72 hours.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients will receive placebo by mouth or by enteral feeding tube every six hours for 72 hours.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Acetaminophen</intervention_name>
    <arm_group_label>Acetaminophen</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Males and Female &gt;=18 years old

          -  Admitted to an Intensive Care Unit

          -  Severe Sepsis

          -  Detectable plasma cell-free hemoglobin

        Exclusion Criteria:

          -  patients who received acetaminophen in the past 48 hours prior to enrollment

          -  intolerance or allergy to acetaminophen

          -  measured AST/ALT &gt;400 U/L in the 24 hours prior to enrollment

          -  chronic liver disease defined by a Child-Pugh score &gt;4

          -  cannot swallow or have no enteral feeding access

          -  patients with no detectable cell-free hemoglobin

          -  patients transitioned to palliative care

          -  pregnant patients or women of childbearing potential without a documented pregnancy
             test
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Vanderbilt University Medical Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2015</verification_date>
  <lastchanged_date>March 19, 2015</lastchanged_date>
  <firstreceived_date>November 26, 2012</firstreceived_date>
  <firstreceived_results_date>March 11, 2015</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Vanderbilt University</investigator_affiliation>
    <investigator_full_name>David Janz</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Sepsis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Acetaminophen</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Acetaminophen</title>
          <description>Patients will receive acetaminophen at the dose of 1 gram by mouth or by enteral feeding tube every six hours for a total of 72 hours.
Acetaminophen</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Patients will receive placebo by mouth or by enteral feeding tube every six hours for 72 hours.
placebo</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="21"/>
                <participants group_id="P2" count="23"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
                <participants group_id="P2" count="22"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Acetaminophen</title>
          <description>Patients will receive acetaminophen at the dose of 1 gram by mouth or by enteral feeding tube every six hours for a total of 72 hours.
Acetaminophen</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Patients will receive placebo by mouth or by enteral feeding tube every six hours for 72 hours.
placebo</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="18"/>
                <measurement group_id="B2" value="22"/>
                <measurement group_id="B3" value="40"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="50" lower_limit="41" upper_limit="64"/>
                <measurement group_id="B2" value="58.5" lower_limit="47.5" upper_limit="63.5"/>
                <measurement group_id="B3" value="55.5" lower_limit="44" upper_limit="63"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="9"/>
                <measurement group_id="B2" value="10"/>
                <measurement group_id="B3" value="19"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="9"/>
                <measurement group_id="B2" value="12"/>
                <measurement group_id="B3" value="21"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>F2-isoprostanes After 72 Hours of Acetaminophen or Placebo</title>
        <description>F2-isoprostanes are a marker of oxidative stress, specifically lipid peroxidation.</description>
        <time_frame>72 hours after randomization</time_frame>
        <safety_issue>No</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>Acetaminophen</title>
            <description>Patients will receive acetaminophen at the dose of 1 gram by mouth or by enteral feeding tube every six hours for a total of 72 hours.
Acetaminophen</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Patients will receive placebo by mouth or by enteral feeding tube every six hours for 72 hours.
placebo</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="18"/>
                  <measurement group_id="O2" value="22"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>F2-isoprostanes After 72 Hours of Acetaminophen or Placebo</title>
            <description>F2-isoprostanes are a marker of oxidative stress, specifically lipid peroxidation.</description>
            <units>pg/mL</units>
            <param>Median</param>
            <dispersion>Inter-Quartile Range</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="33.4" lower_limit="24.97" upper_limit="43.47"/>
                  <measurement group_id="O2" value="40.15" lower_limit="29.67" upper_limit="61.8"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority>No</non_inferiority>
            <p_value>0.353</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>In-hospital Mortality</title>
        <time_frame>Patients will be followed through the end of their hospital stay, an average of 5 weeks</time_frame>
        <safety_issue>No</safety_issue>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Serum Creatinine After 72 Hours of Treatment With Acetaminophen or Placebo, Adjusted for Baseline Creatinine</title>
        <time_frame>72 hours</time_frame>
        <safety_issue>No</safety_issue>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Participants were followed for the duration of hospital stay, an average of 4 weeks</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Acetaminophen</title>
          <description>Patients will receive acetaminophen at the dose of 1 gram by mouth or by enteral feeding tube every six hours for a total of 72 hours.
Acetaminophen</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Patients will receive placebo by mouth or by enteral feeding tube every six hours for 72 hours.
placebo</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>AST or ALT &gt;400 U/L</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. David R Janz, MD, MSc, Assistant Professor of Medicine</name_or_title>
      <organization>LSU Health Sciences Center New Orleans</organization>
      <phone>504-568-3167</phone>
      <email>djanz@lsuhsc.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>
